The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.
UniQure has announced its intention to seek FDA approval for its Huntington's disease gene therapy. This development follows a period of public debate between the company and FDA leaders concerning the clinical trial data supporting its application. The decision signals a…
Market Samachar is a news aggregator. This article was originally published by Business News. Tap the button above to read the full story on their site.